Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.

1,406 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Targeting autophagy in cancer (2018, background): “It also has been observed that autophagy dictates the immunogenicity of cell death in tumors.(91) The absence of an appropriate response to autophagy induction in tumor cells potentially could predict resistance to immune-checkpoint blocker therapies in human cancers.”
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors. (2016, neutral): “This is determined by the presence of antigen-presenting DCs in the proximity of dying or apoptotic tumor cells (Broz et al., 2014; Galluzzi et al., 2015; Sandel et al., 2005), by existing neoantigens or high mutational load allowing high-avidity TCR engagement and proliferation (Tran et al.,…”
PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression (2017, background): “There is accumulating evidence indicating that conventional and targeted anticancer therapies also affect tumor-targeting immune responses (17).”
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells (2016, background): “It is increasingly clear that T lymphocytes recognizing tumor-derived peptides presented by major histocompatibility complex (MHC) molecules play a central role in immunotherapy and in conventional chemo-radiotherapy of cancer (Galluzzi et al., 2015).”